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Many important questions regarding pathophysiology and treatment of cerebral sinove-
nous thrombosis need clarification and may depend on further knowledge on the etiology,
site, extension and recanalization of the thrombosis. We studied these variables in a cohort
of children and adolescents from seven Portuguese Centers. We conclude from our results
that the deep venous system and the superior longitudinal sinus are less frequently
affected with thrombosis but have a greater potential for serious neurologic disease and for
major sequelae. Non-recanalization, at least in the long term, is not an adverse prognostic
factor. Extensive propagation of the thrombus from the initial site of origin seems to be
common. The early identification of risk factors and their treatment coupled with an
aggressive attitude towards diagnosis and treatment for thrombosis involving the deep
venous system would be warranted.
ª 2008 European Paediatric Neurology Society. Published by Elsevier Ltd. All rights
reserved.1. Introduction prognostic significance. Idiopathic CSVT (absence of an etio-Children with cerebral sinovenous thrombosis (CSVT) are at
risk for complications in the acute phase and may have long
term sequelae.
In adults several factors affect adversely the prognosis in
the acute phase: impaired consciousness, thrombosis of the
deep venous system, right hemisphere hemorrhage and
a posterior fossa lesion.1–7 In the long term these factors retain44; fax: þ351 21 312 6963.
-saude.pt (J.P. Vieira).
ean Paediatric Neurologylogic or triggering factor) occurred in 15% of patients in the
largest study in adults.1
The studies in children reached similar conclusions but the
prognosis depends substantially also on the etiology of CSVT
so the differences in prognosis are very likely also related to
diverse etiologies.8–16
Recanalization has been studied in children and in adults
with CSVT.7,11,15,16,21 A total of 18–27% of adults and 11–16% ofSociety. Published by Elsevier Ltd. All rights reserved.
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studies also reportedpartial recanalization inup to 42%.11,13,15,16
Non-recanalization or partial recanalization is not associ-
ated with worse prognosis, very likely because transverse
sinus thrombosis is more frequently associated with persis-
tent thrombosis.
Treatment with anticoagulants in the acute phase, largely
extrapolated from the current guidelines in adults,17 became
an accepted practice, but the decision to withhold anti-
coagulation in a subgroup of patients with good prognosis,
instituting thrombolysis for those who continue to deteriorate
despite anticoagulation or selecting patients who must
prolong anticoagulation because they are at high risk for
recurrence are still largely debated questions without a defi-
nite answer.
We tried to establish in our group of patients correlations
between etiologic factors, the site and extension of throm-
bosis, the clinical picture in the acute phase, recanalization
and long term sequelae.2. Materials and methods
We included retrospectively in this study all children and
adolescents (neonates to 18 years of age) with a diagnosis of
sinovenous thrombosis, seen during the period of January/
2001 to December/2007, at the Institutions participating in the
study.
All patients underwent magnetic resonance imaging (MRI)
andmagnetic resonance venography (MRV) in the acute phase
to establish the diagnosis.
Clinical data (age, gender, underlying disease or triggering
condition, neurologic symptoms and signs, long term neuro-
logic deficits and treatment) were collected from the patient’s
records by their attending neurologist.
The clinical and imaging findings were evaluated consid-
ering the role played by the CSVT vs. the primary etiologic
disorder.
We classified as possibly related to CSVT: headache,
depressed consciousness, papilledema, VIth nerve palsy, IIIrd
nerve palsy in cases of cavernous sinus thrombosis and focal
neurologic signs and seizures attributed to brain lesions with
a pattern consistent with venous infarction.
We also evaluated the symptoms and signs and imaging
findings in order to establish alternatively or concomitantly
a causal relationship with the disorder(s) implicated in the
etiology of CSVT.
We had follow-up data for all children included in the
study. The follow-up was done by the neurologist partici-
pating in the study. Median and mean follow-up duration
were respectively 3.5 and 2.5 years.
We considered major sequelae major cognitive or motor
deficits and epilepsy and defined as minor sequelae minor
hyperactivity, minor motor incoordination and cranial nerve
palsies (more frequently oculomotor nerve palsies).
Data from the prothrombotic studies were also collected.
Not all studies were performed in all patients because
knowledge in the field expanded. Most of the following
investigations were performed: blood count, cholesterol,
tryglicerides, fibrinogen, antithrombin III, proteins S and C,serum homocysteine, factor VIII, antiphospholipid and anti-
cardiolipin IgG antibodies, and a genetic study for Factor V
Leiden, prothrombin gene 20210 mutation, thermolabile
methyleno tetrahydrofolate reductase and plasminogen acti-
vator inhibitor gene 4G–5G polymorphism. Blood tests
involving acute phase reactants (proteins C and S, fibrinogen
and factor VIII) were repeated later to make sure that the
abnormal values found initially were not transitory and
secondary to acute thrombosis. The effect of warfarin and
heparin on the blood tests (specifically on antithrombin III
and proteins C and S blood levels) was also taken into account.
The genetic investigations were performed, for all patients in
a Molecular Genetics referral Laboratory (Instituto Ricardo
Jorge, Lisbon, Portugal). The other studies were done at each
Institution participating in the study.We confirmedpreviously
that the techniques involved were accurate and comparable.
The MRI and MRV findings were reviewed, at each Insti-
tution, and followed the protocol design for this study estab-
lished with the collaboration of a Neuroradiologist: sinuses or
veins affected and parenchymatous brain lesions were
recorded. Forty three patients were submitted later (within 1–
24 months) to a follow-up MRI and MRV to evaluate both
recanalization and residual brain lesions. We considered
partial recanalization only when irregular and limited flow
was present in the involved sinus with consideration of
previously reports documenting certain areas of slow flow in
the dural sinuses as a normal variant. In some cases we
confirmed this finding on a subsequent study.
According to the updated version of the Declaration of
Helsinki the study data were collected anonymously so that
the investigators could not have access to the patients’
identification.
Statistical analysis was made with SPSS for Windows
14.0.3. Results
3.1. Epidemiology
Fifty three children were included in the study, from seven
different centers.
Thirty (56.6%) were male and 23 (43.4%) were female.
Median age was 4 years (minimum 3 days, maximum
17 years); six patients (11.3%) were newborns.
3.2. Underlying disease or triggering condition
Infection, especially mastoiditis, was the most frequent trig-
gering factor, responsible for 30 cases (56.6%). In seven chil-
dren (13.2%) idiopathic CSVT was diagnosed. Three out of the
seven patients in the idiopathic group were neonates.
In Table 1 we list the triggering conditions or underlying
diseases.
3.3. Affected dural sinuses and veins
Transverse and sigmoid sinuses were the most frequently
affected, followed by the superior longitudinal sinus (Table 2).
Thirty children (52.6%) had multiple sinuses involved.
Table 1 – Triggering factors or underlying systemic
diseases identified in our patients.
Etiologic factor Number (%)
Infection 30 (56.6)
– Mastoiditis 23 (43.4)
– Meningitis 7 (13.2)
Hypercoagulable states 9 (16.3)
– Nephrotic syndrome 2 (3.8)
– Maternal autoantibodies 1 (1.9)
– Lupus 1 (1.9)
– l-asparaginase 5 (9.4)
Other 7 (13.2)
– Trauma 1 (1.9)
– AVM embolization 1 (1.9)
– Dehydration 1 (1.9)
– Surgery craneopharingioma 1 (1.9)
– Diabetes; dehydration 1 (1.9)
– NF1 1 (1.9)
– Sturge–Weber syndrome 1 (1.9)
Idiopathic 7 (13.2)
AVM: arteriovenous malformation; NF1: neurofibromatosis type 1.
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Six patients (11.3%) had no neurologic symptoms or signs and
CSVT was discovered when MRI was performed due to other
symptoms and signs (more often these patients had
mastoiditis).
CSVT was diagnosed on the 4th day of disease (median).
Diagnosis was earlier when the venous thrombosis was associ-
ated with focal neurological signs (2 days vs. 10 days; P¼ 0.046).
Fifteen patients (28.3%) presented with combinations of
headache, papilledema, vomiting and VIth nerve paralysis
associated with lateral sinus thrombosis and mastoiditis.
CSVT associated with mastoiditis had a more uniform
clinical presentation than thrombosis associated with other
etiologies: papilledema (41.3% vs. 14.2%; P ¼ 0.038) and VIth
nerve palsy (44.8% vs. 0%; P ¼ 0.0001).Table 2 – Dural sinuses and veins involved in CSVT.
Affected
Sinus
Number of
sinuses
or veins
involved
with
thrombosis
Percentage in
relation to
number of
patients (%)
Percentage in
relation
to number of
‘‘vessels’’
affected (%)
Transverse
sinus
36 67.9 40.5
Sigmoid sinus 18 34 20.3
Superior
longitudinal
sinus
14 26.4 15.7
Straight sinus 10 18.8 11.2
Cavernous
sinus
5 9.4 5.6
Jugular vein 5 9.4 5.6
Cortical vein 1 1.9 1.1Depressed consciousness occurred in 19 patients and was
more frequent instraightsinus thrombosis (80%vs.30%P¼ 0.09).
The combination of depressed consciousness, seizures and
focal signs was associated with longitudinal sinus thrombosis
(68.8% vs. 32.4% P ¼ 0.019).
Seizures weremore common in newborns (83.3% vs. 17.1%;
P ¼ 0.002) and in association with longitudinal sinus (45.5% vs.
15.2%; P ¼ 0.042) and with straight sinus thrombosis (50% vs.
16.3%; P ¼ 0.05).
Headache, depressed consciousness, meningeal signs,
cranial nerve palsies, focal signs and seizures were attribut-
able, at least partly, to bacterial meningitis in five patients.
Depressed consciousness also occurred in one patient with
hypernatremic dehydration, and peripheral facial palsy was
a complication of acute otitis media and mastoiditis in
another patient.
3.5. Treatment
Thirty six patients (67.9%) were submitted to anticoagulant
therapy during the acute phase. Therapeutic regimens varied
in different centers, but in all patients but one the treatment
included heparin or a low molecular weight heparin initially.
In 16 children anticoagulation with oral warfarin was started
after the acute phase and maintained for several months.
Seventeen childrenwerenot anticoagulated andwere treated
only for the etiological factors (this group included six neonates).
3.6. Prothrombotic factors
Eighteen children were not investigated for associated
prothrombotic factors. Most of these patients were the
earliest to be diagnosed; in one child CSVT was associated
with L-asparaginase treatment for leukemia and in another
CSVT occurred in association with embolization of an
arteriovenous malformation.
Of the remaining 35 children, 14 (40% of the patients
studied) had a prothrombotic condition (Table 3).
3.7. Outcome
There were no deaths in our group of patients with CSVT.
Overall 43.4%had long termneurologic deficits,major in 24.5%
(13 patients) and minor in 18.8% (10 patients).Table 3 – Prothrombotic factors identified in our patients.
Prothrombotic factor Number
Mutations of the PAIi gene 6*
Anti-phospholipid/anti-cardiolipin antibodies 2
Homocistinemia 1
Deficits of antithrombin III 1
Mutations of factor VIII 2
Mutations of the MTHFR gene 1*
Leiden’s factor V 1
Mutations of the prothrombin gene 1
PAIi: plasminogen activator inhibitor 1; MTHFR: methyleno tetra-
hydrofolate reductase.
* 1 composite heterozygous for PAII/MTHFR mutations.
Table 5 – Recanalization (study of other possible risk
factors).
p OR (CI)
Age 5.6 years vs. 6 years 0.77 –
Transverse sinus
(any etiology)
66.7% vs. 60% 0.75 0.77 (0.2–2.8)
Straight sinus 61.8% vs. 66.7% 1.0 1.23 (0.2–5.8)
Sup. longitudinal sinus 62.1% vs. 64.3% 1.0 1.1 (0.3–4.1)
Meningitis 71.4% vs. 61.1% 0.69 1.5 (0.2–9.3)
Anticoagulation 54.8% vs. 83.3% 0.15 0.2 (0.04–1.3)
Prothrombotic factors 66.7% vs. 37.5% 0.25 1.02 (0.3–3.6)
Sequelae (any) 62.5% vs. 63.2% 1.0 1.5 (0.3–6.9)
Major sequelae 70% vs. 60.6% 0.7 0.3 (0.09–1.2)
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cranial hypertension with a protracted course and needed
surgical treatment (lumboperitoneal shunt and later a ven-
triculoperitoneal shunt because of occlusion of the lumbo-
peritoneal shunt). We considered this a major sequela.
Not all patients’ neurologic deficits were due to the CSVT.
In four patients with bacterial meningitis we considered that
the sequelae were more appropriately attributable to the
underlying disease and in another patient withmeningitis the
sequelae were clearly due to multiple factors (CSVT, vascu-
litis, hydrocephalus).
Major sequelae occurred mainly in younger children
(median age 1.67 years vs. 6 years; P ¼ 0.006), and in children
with seizures (50% vs. 11.1%; P ¼ 0.007). Straight sinus
thrombosis was associated with a higher risk of major
sequelae (50% vs. 14.2%; P ¼ 0.037).
A late diagnosis of venous thrombosis was associated with
a better prognosis: children with major sequelae had a diag-
nosis on the 2nd day of disease (vs. 8th day; P ¼ 0.05).
Transverse sinus thrombosis was associated with good
outcome for bothmajor and any sequelae (P ¼ 0.003 and 0.001,
respectively).
Major sequelae and any sequelae were significantly corre-
lated with the clinical presentation of any combination of
depressed consciousness, focal neurologic signs and seizures
at presentation (43.7% vs. 10%; P ¼ 0.009 and 60.8% vs. 30%;
P ¼ 0.03, respectively).
We have found no correlation betweenmajor sequelae and
anticoagulation and with the presence of prothrombotic
factors (Table 4).3.8. Recanalization
In ten patients a follow-up MRI/MRV was not performed.
In the remaining 43 patients MRI/MRV was repeated
1–24 months after the acute disease.
Six patients (13.9% of the patients evaluated) did not
recanalize their thrombosis and ten had partial recanalization
(23.2% of the patients evaluated).
Transverse sinus thrombosis associated with mastoiditis
(but not with other etiologies) was statistically associatedwith
non-recanalization (P ¼ 0.051).
Jugular vein thrombosis with sigmoid and transverse sinus
thrombosis was also correlated inversely with recanalization
(P ¼ 0.022).
A longer duration of symptoms at the time of diagnosis of
CSVT was also correlated with non-recanalization (P ¼ 0.051).
In Table 5 we present data from correlation between
recanalization and other variables.Table 4 – Major sequelae (study of other possible risk
factors).
p OR (CI)
Anticoagulation 14.3% vs. 38.1% 0.25 0.2 (0.05–1.5)
Prothrombotic factors 19.4% vs. 35.3% 0.3 0.4 (0.1–1.6)4. Discussion
We have found a higher proportion of male (56.6%) vs.
female (43.4%) patients, concordant with previous
reports.9–11,13–15
The majority of these reports on CVST in children found
a peak incidence of CSVT in neonates8,9,12–14,16 but our
patients distributed uniformly across all age groups.
In seven of our patients (13.2%) no underlying disease or
triggering condition was identified. Idiopathic cases were less
frequent in other series as reported by Se´bire (no idiopathic
CSVT),13 Bonduel (three idiopathic cases in 38 patients)14 and
deVeber (only 2% of 160 children did not have a clinical risk
factor).9 Nevertheless Heller et al.11 did not identify a clinical
risk factor for CSVT in 29.5% of 149 patients and Carvalho
et al.10 reported on 31 children (seven out of 31 patients had no
clinical risk factor). While this discrepancy may be due to
referral bias; idiopathic CSVT in children is probably slightly
less frequent than in adults (15% idiopathic CSVT were
reported in the International Study on Cerebral Vein andDural
Sinus Thrombosis).5
The triggering factor(s) for thrombosis in our patients
included a greater proportion of mastoiditis (43.4%). This is
probably related to epidemiological factors that are outside
the scope of this work.
As a consequence of this predominance of mastoiditis,
transverse sinus thrombosis is disproportionately repre-
sented in our group of patients (40.5% of all ‘‘vessels’’ involved
and 67.9% of all patients).
We have found that various combinations of transverse,
cavernous, sigmoid sinus and jugular vein thrombosis were
frequently found in this setting. The particular combination of
transverse plus cavernous sinus thrombosis was not reported
previously and was found in four of our patients with
mastoiditis; possibly in these cases the thrombus propagated
from the lateral to the cavernous sinus through the petrous
sinus.
Se´bire et al. reported, in a series of 42 patients, transverse
sinus thrombosis in 47% and mastoiditis was also the trig-
gering factor in a significant number of their patients (42%).13
Transverse sinus thrombosis, isolated or associated with
thrombosis of other sinuses, was less frequently seen in other
pediatric series: 20.7%, 31% and 12% were reported respec-
tively by Heller,11 Bonduel14 and Kenet.15
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triggering condition a prothrombotic state was also frequently
found. We had similar results with our group of patients.
Symptoms and signs in our patients were concordant with
those reported by other studies.
Our patients with thrombosis of the straight sinus (80%) or
longitudinal sinus (56.3%) had significantly more often
depression of consciousness compared to patientswith lateral
sinus thrombosis (38.9%).
Seizures were more common in newborns and in associa-
tion with straight and longitudinal sinus thrombosis while
lateral sinus thrombosis characteristically had a subacute
presentation with symptoms and signs of intracranial
hypertension.
Long term major neurologic deficits in our patients were
associated with younger age, seizures, decreased level of
consciousness, focal neurologic signs and with thrombosis
of the straight sinus. This was also reported by other
studies in children.9,13 Studies in adults besides similar
clinical risk factors identified worse prognosis with age
greater than 37.1
We also found that the prognosis depends significantly, in
some cases, on the etiologic factor for thrombosis. In four
patients the sequelae were more likely due to bacterial
meningitis and in another the residual neurologic deficits
were of multifactorial origin (bacterial meningitis, hydro-
cephalus, venous thrombosis and arteritis).
MRV is a technique dependent on blood flow and slow
flow occurs normally in parts of the intracranial venous
system. Non-visualization of part of a sinus on MRV may
therefore occur without thrombosis. This was reported at
the origin of the lateral sinus18–20 and, in neonates, in the
posterior part of the longitudinal sinus.20 In addition
a normal hypoplastic sinus (usually the left lateral sinus)
can also be mistakenly interpreted as partially throm-
bosed.19 Therefore we did not consider non-recanalization
or partial recanalization any patient’s MRV presenting one
of these normal variants.
Recanalization was investigated in five studies in adults7
but one study did not distinguish between partial recanali-
zation and absent flow. Globally 16% of adult patients did not
recanalize their thrombosis.7 Lateral and sigmoid sinuses
weremore frequently affectedwith persistent thrombosis and
non-recanalization at 4 months usually was incompatible
with later resolution of the thrombosis.7,21,22
Three reports on CSVT in children investigated recanali-
zation and reported non-recanalization in 11–16%11,13,15 and
partial recanalization in 41% and 42% of patients.11,15
The total number of patients in our series with persistent
thrombosis or with partial recanalization is slightly lower
(37.1%), and we had a smaller proportion of cases with partial
recanalization (23.2%).
In our series transverse sinus thrombosis associated with
mastoiditis (but not with other etiologies) was statistically
associated with a greater risk for non-recanalization.
Doppler studies documented that flow is slower in the
transverse sinus23 and the greater volume of this sinus and
longer duration of symptoms before diagnosis of thrombosis
may predispose to propagation and to organization of thethrombus. In addition, septic thrombophlebitis may cause
a more aggressive endothelial injury.
In theory recanalization could be viewed as an important
goal in the treatment of venous thrombosis but, as others
have reported previously, we have found that recanalization
in the long term did not correlate positively with a better
prognosis.
Transverse sinus thrombosis secondary to mastoiditis was
frequently compatible with recovery without sequelae
regardless of the recanalization status.
The prognosis is apparently more dependent on the
localization of thrombosis. Thrombosis affecting the deep
venous system may have more serious consequences in the
acute phase and is associated with a greater risk for long term
sequelae. Nevertheless the deep venous system recanalizes
more frequently and probably earlier.
The events in the acute phase are largely unknown at
present. Venous stasis, endothelial injury and genetic and
acquired prothrombotic factors may play a role in the
processes of thrombus formation, propagation, organization
and dissolution.
Doppler studies in peripheral vein thrombosis
concluded that thrombus propagation is a rare and usually
limited event24 but peripheral veins have valves that
probably limit propagation. Thrombus propagation is
probably more extensive and more frequent in the dural
sinuses.
We think that the imaging data from our patients with
transverse sinus thrombosis secondary to mastoiditis support
the notion that thrombosis in the intracranial venous sinuses
carries a significant risk of extension from the initial site of
thrombus formation. In 14 of 23 (60.9%) of our patients with
mastoiditis and lateral sinus thrombosis other sinuses were
also affected.
Recurrence of SVT in the adult population is infrequent
(2.2% reported in the ISCVT study, five/100 patients-years
reported by Gosk-Bierska).1,25
The Canadian study from DeVeber et al. in 160 children
with CSVT identified 12 children with recurrent thrombosis.9
The study by Kenet et al. in 266 children with CSVT found
that venous thrombosis recurred in 3%. In this study non-
recanalization significantly increased the likelihood of recur-
rence of thrombosis.15
In our study there were no cases of recurrence of the CSVT
after a period of follow-up from 13 months to 6 years.
As final conclusions we point out that in CSVT depressed
state of consciousness, thrombosis of the deep venous system
and/or of the superior longitudinal sinus and extensive
thrombosis should be viewed as ominous prognostic factors.
The predisposing conditions should be aggressively treated
and the patients clinically monitored for neurologic compli-
cations. Thrombus propagationmay be a frequent occurrence.
Recanalization in the long term is not a significant factor for
outcome but we believe that in the short term it could be
relevant and repeating MRI in the acute phase could give
additional information to guide the clinical management of
a selected group of patients that present with clinical and
imaging findings linked to a greater risk for complications and
to poor prognosis.
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